Buyout news from FiercePharma
NewsBayer CEO scoffs at takeover talk
Market watchers can wag their tongues all they like, says Bayer CEO Werner Wenning (photo). The company isn't... Read more...
Japanese pharma to pay $1.4B for Sciele
In yet another Japanese pharma takeover, Shionogi has agreed to pay $1.42 billion for the Atlanta-based drugmaker Sciele Pharma. That's a $31-per-share cash offer, a 61 percent premium over Sciele's... Read more...
Higher Genentech bid, bigger exodus?
Would a bigger bid for Genentech just induce more scientists there to exit out the back door as Roche comes in the front? That's one of the questions arising about this potential mega-merger. In... Read more...
Analysts: BMS lowballing ImClone
Who would you lay bets on: Carl Icahn or Jim Cornelius? The Bristol-Myers Squibb CEO has... Read more...
Icahn throws wrench into ImClone offer
Carl Icahn has spoken--and he's not satisfied. Bristol-Myers Squibb's $4.5 billion bid for ImClone, he says, is too... Read more...
Bid-happy analysts play matchup
Analysts just can't get their minds off which drugmakers might make a deal next. The most recent suspects are Bayer and Onyx, which are partnered on the
BMS bid triggers deal talk
Have you noticed that one deal announcement inevitably leads to speculation of another? Well, yesterday's bombshell that
Roche offer could swallow Genentech
Genentech is one of the earliest and most successful biotech companies out there, but can it stay biotech's golden child following a buyout by Roche? That's the question on at least a few industry... Read more...
Roche has ways to limit Genentech price
The Roche offer for Genentech is still reverberating through the news today, spawning all sorts of price speculation and predictions about Genentech's probable future if owned outright by the Swiss... Read more...
PPF leaves Zentiva to Sanofi
PPF Group has bowed out of the competition for the Czech generics maker Zentiva, saying it has "certain doubts about the real value of the company" -- and that it doesn't want to end up in a bidding... Read more...
| Press ReleasesPRESS RELEASE: Bristol-Myers Squibb to Buy Partner Adnexus Therapeutics for $430 Million Bristol-Myers Squibb to Buy Partner Adnexus Therapeutics for $430 Million PRINCETON, N.J. and WALTHAM, Mass., Sept. 24 -- Bristol-Myers Squibb Company and Adnexus(TM) Therapeutics announced today Read more >> |
Get more Buyout coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
